Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review
Author:
Publisher
Springer Science and Business Media LLC
Subject
General Earth and Planetary Sciences,General Environmental Science
Link
https://link.springer.com/content/pdf/10.1007/s13691-020-00430-6.pdf
Reference16 articles.
1. Macher-Goeppinger S, Roth W, Wagener N et al (2012) Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol 25:308–315
2. Srigley JR, Delahunt B, Eble JN et al (2013) The international society of urological pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489
3. Argani P, Olgac S, Tickoo SK et al (2007) Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 8:1149–1160
4. Sidhar S (1996) The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 5:1333–1338
5. Mathur M, Das S, Samuels HH (2003) PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequesteration. Oncogene 22:5031–5044
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Four years of natural progressive course: A rare case report of juvenile Xp11.2 translocations renal cell carcinoma with TFE3 gene fusion;Open Medicine;2024-01-01
2. Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis;Journal of Kidney Cancer and VHL;2023-09-27
3. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma;Human Vaccines & Immunotherapeutics;2023-01-02
4. Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report;Frontiers in Pharmacology;2022-08-11
5. A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment;International Cancer Conference Journal;2022-02-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3